Alnylam Pharmaceuticals | ALNY - Ebitda

Aktienkurs
305.54
Täglich Wechseln
-8.25 -2.63%
Monatlich
-7.05%
Jährlich
21.46%
Q2 Prognose
299.00




Ebitda Veränderung Datum
Acadia Pharmaceuticals USD 35.76M 447K 2025-09
Agios Pharmaceuticals USD -115.49M 10.3M 2025-09
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Arrowhead Research USD 64.2M 223.53M 2025-09
BioCryst Pharmaceuticals USD 51.7M 30.14M 2025-09
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Incyte USD 414.5M 92.42M 2025-12
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 5.84B 235M 2025-09
PTC Therapeutics USD -70.99M 91.62M 2025-12
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Sanofi EUR 5.66B 3.77B 2025-09
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
Takeda JPY 448.13B 173.98B 2025-12
Tectonic Therapeutic USD -21.18M 365K 2025-12
Ultragenyx Pharmaceutical USD -156.79M 65.44M 2025-09
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09
Xencor USD -51.05M 55.28M 2025-12